SecBot SecBot

IMNM

Immunome Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001472012 Biotech & Drug Discovery
$17.61 −1.16 (−6.18%)
Nov 16 4:00 PM ET · prev $18.77
Market cap
$2.2B
Mid cap
Consensus
Buy
91% Buy or better · 23 analysts
Median target
$36.00
+104% · range $23.00–40.00
1 year
−2.9%
from $18.13 · Nov 17
30 days
+5.0%
from $16.77
52-week range
$16.47–29.83
−41% from high · low Oct 16
Avg volume 20D
1.54M
shares / day
Short interest
16.17M
≈13.7% of shares · −6.4%
Days to cover
12.8
at average volume
Insider net
−$16.1M
1 buyer · 6 sellers · since Jun 5
New fund stakes
1
Q3 2026 13F · 0 exits
Filing reports
20
analyzed by SecBot
SecBot read MIXED 9 reports · 90 days
Balance 2 bearish · 3 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 5/9 ·Next FDA decision date, Apr 28, 2027

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $116.9K at an average $19.48. 6 insiders sold $16.2M. Price is 10% below their cost.

  • InstitutionsBULLISH

    Q3 2026: 21 added (1 new), 14 trimmed or exited.

  • AnalystsBULLISH

    21 of 23 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.569 → −$0.600 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −6.4% to 16.17M shares. 12.8 days to cover, ≈13.7% of shares.

  • TrendRANGE

    14% below its 50-day average.

Who's buying

13F· Q3 2026
1
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYTRIM1,688,972$36.3M
BNP PARIBAS FINANCIAL MARKETSADD573,174$12.3M
Candriam S.C.A.TRIM489,853$10.6M
Nuveen, LLCADD436,768$9.4M
FEDERATED HERMES, INC.DOUBLED305,699$6.6M
Qube Research & Technologies LtdTRIM279,624$6.0M
Invesco Ltd.DOUBLED258,085$5.6M
SEI INVESTMENTS CODOUBLED206,892$4.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

23 analysts
Buy 91% rate it Buy or better
Strong Buy6Buy15Hold2Sell0Strong Sell0
12-month targets · 15 analysts

Price is below the lowest target. Median implies +104%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 10, 2026Stifel
MAINTAIN
MAINTAINHold
Nov 10, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
Oct 27, 2026Wedbush
REITERATE
REITERATEOutperform
Oct 16, 2026William Blair
INITIATE
INITIATEOutperform
Oct 1, 2026Stifel
INITIATE
INITIATEHold
Sep 21, 2026Alliance Global Partners
INITIATE
INITIATEBuy

Insider ledger

Form 4
$116.9K
bought · 1 insider
$16.2M
sold · 6 insiders
−9.6%
vs their $19.48 cost
DateInsiderTypeValue
Sep 11, 2026
Higgins Jack
Chief Scientific Officer
Sep 11, 2026
SELL$334.2K
Sep 11, 2026
Higgins Jack
Chief Scientific Officer
Sep 11, 2026
EXERCISE$24.3K
Sep 11, 2026
Higgins Jack
Chief Scientific Officer
Sep 11, 2026
GIFT8,800 sh
Aug 12, 2026
Barchas Isaac
Director
Aug 12, 2026
SELL$301.1K
Aug 11, 2026
Barchas Isaac
Director
Aug 11, 2026
SELL$1.6M
Aug 10, 2026
Barchas Isaac
Director
Aug 10, 2026
SELL$264.0K
Aug 7, 2026
Barchas Isaac
Director
Aug 7, 2026
SELL$397.4K
Aug 6, 2026
Barchas Isaac
Director
Aug 6, 2026
SELL$543.1K

Earnings setup

Estimates
−$0.60
EPS estimate, this quarter
−5%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.60-$0.71–-$0.41-1.9%$0.00
Next Q-$0.74-$0.90–-$0.58-8.7%$0.00
Current FY-$2.50-$2.95–-$2.12-9.3%$0.00
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
16,173,694
shares short
-6.4%
vs prior settlement
12.8
days to cover
≈13.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 Earnings calendar
IMNM Q3 2026 Earnings Scheduled · 2026-11-16
Nov 9, 2026 SEC
Immunome filed an automatic shelf registration (S-3ASR) as a well-known seasoned issuer, including an ATM sales…
S-3ASR · Impact 3/10
Nov 9, 2026 SEC
Immunome filed an automatic shelf registration statement (S-3ASR) to register 4,425,487 shares of common stock for…
S-3ASR · Impact 3/10
Sep 30, 2026 Inst.
MORGAN STANLEY · TRIM
1,688,972 shares ($36.3M)
Sep 30, 2026 Inst.
BNP PARIBAS FINANCIAL MARKETS · ADD
573,174 shares ($12.3M)
Sep 11, 2026 Insider
Higgins Jack sold 13,200 shares
Chief Scientific Officer @ $25.32 ($334.2K)
Sep 11, 2026 Insider
Higgins Jack acquired via exercise 18,000 shares
Chief Scientific Officer @ $1.35 ($24.3K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
6 drugs tracked · Drug pipeline →
Upcoming
Recent

SecBot reports

20 filings · 5 bullish · 3 bearish · 2 mixed · 10 neutral
All IMNM filing & press-release reports (20)